Haven't had much time lately? Here's what you may have missed in the last few months
The ESMO Tumour Portals allow you to find the key educational resources in your field of interest
23 Jan 2015
Human epidermal growth factor receptor 2-positive breast cancer patients with tumours expressing a 14-immune gene signature may benefit more from...
22 Jan 2015
Lapatinib–capecitabine fails to show greater efficacy than trastuzumab–capecitabine for the treatment of metastatic breast cancer
21 Jan 2015
The final analysis of a phase III trial shows that metastatic prostate cancer patients given abiraterone acetate plus prednisone have significantly...
20 Jan 2015
Increasing the radiation dose or adding cetuximab therapy fails to improve non-small-cell lung cancer patient overall survival after...
G. Curigliano discusses what Antibody drug conjugates (ADCs) are and their mechanism of action in cancer cells. There are currently 2 approved ADCs in oncology/haematology and many trials are currently ongoing accross tumour types. He concludes that this could be the future for cancer treatment, specifically where no identifiable Antigen can be targeted by MoAbs.